All right. Good day, everybody. My name is Ash Verma. I cover Small-Cap Biotech and Pharma at UBS, and really excited to host ACADIA Pharmaceuticals. Just to give a quick background, ACADIA has DAYBUE and NUPLAZID. I will just pass it on to Catherine, if you can talk a little bit about the story in terms of where the focus of the growth opportunity is in both the products, and then we can talk about the pipeline and other things after that.
Sounds good. We just delivered our quarter results. As a company, we delivered $342 million, which was a 22% year-over-year growth against both the brands that you just talked about. DAYBUE was $140 million, which delivered 39% year-over-year growth. Within that, we also raised our guidance for the year to between $505 million and $520 million. NUPLAZID delivered $202 million, and that was a 12% year-over-year growth, most of that driven by volume. In terms of other highlights that we have shared this quarter, we also had a successful weight-banded dosing approved for our DAYBUE product, which gives us protection out to 2041, which is an additional five years in the U.S., and we are also pursuing that in Europe. We have got $970 million+ on the balance sheet.
Looking forward to also ensuring that we focus that effort on some BD spending.
Great. Awesome. Yeah, thanks for that. I think it is an interesting story. Definitely a lot of growth has come back in a big way, especially, Catherine, since you have been here. So that has been good to see.
Yeah.
Especially with the NUPLAZID IP getting extended last year, and then the DAYBUE doing really well. Yeah, pretty great story, very nicely done. I guess one of the things that people want to see more diversification, obviously, and some of the pipeline programs, it's always there's some inherent risk in these indications, right, when you're looking at it. So when you think about what has happened, either with the negative symptoms of schizophrenia or PWS or now with the ADP, does that change your view in terms of whether you can source the pipeline internally, or do you necessarily need external innovation to come from your BD activities?
Yeah. No, I think we are really excited about our pipeline right now. As you just referred, we just released our RADIANT phase II study, which did what it was intended to do, which was help us design an optimized phase III program that we are designing for regulatory success. So we'll come onto some more specifics around that. We also have the ongoing phase II program in Lewy body dementia psychosis, which we've announced now we'll get the results in Q4 of next year. And a study that we start to get more questions about now, which is ACP-211 in major depressive disorder, and we are looking for phase II results in the second half of next year. So yes, we weren't successful with Prader-Willi syndrome, unfortunately.
But we're super excited about those opportunities that I've just referred to, because we believe together they could offer us real value in terms of peak potential, and along with our [inaudible] product, over $11 billion of peak potential, which is a sizable opportunity for us at ACADIA. But in addition, we are looking to utilize the balance sheet to drive some strategic inorganic growth. And as we've been saying, we're looking in key areas for that, and I'm happy to elaborate a little bit more if that's useful. But we're looking for both, and I think our pipeline in itself offers us some real opportunity, and we're very excited to be investing in that right now.
Great. Awesome. Yeah, I'm looking forward to sort of more fattening of the pipeline here. We'll see more busier pipelines going forward, I guess. Okay, so maybe if I focus on DAYBUE to begin with.
Yeah.
Just help us understand, I think in the last one and a half year, definitely things have improved quite a bit. What are some of the strategies that you've deployed to ramp up that growth?
Right.
Yeah.
Yeah. Last year, as you may remember, we expanded our field force to allow us to get into the community a little bit more specifically, because 65% of the Rett patients actually are treated by community physicians. So that's now fully in action. As you know, earlier this year, we launched a new formulation of DAYBUE, which in itself, for life cycle management, doesn't sound that exciting. But for us, we knew it was really important for growth, because we were able to listen to the community, and they asked for a product that was more flexible for their children and something that had a lower volume. This powder for oral solution allows them to sprinkle it into a liquid other than water, and so they can use a flavor that their daughter likes. Also, it's a smaller volume.
The combination of a better flavor profile and a smaller volume is really driving renewed interest, both from naive patients and patients that have previously discontinued. So in terms of the growth opportunity now for DAYBUE within the U.S., that's very exciting. Beyond the U.S., I've been very focused on expanding our global footprint. As you know, we had the DAYBUE approval reversed, the decision reversed, and we got approval in Europe in the last quarter, and we launched in Germany in October. So we now are selling commercial product in Germany. Yesterday, we announced a distribution deal with KYORIN Pharmaceutical, a Japanese pharmaceutical company, to allow us to file in Japan and commercialize in Japan in 2028.
The strategy for driving DAYBUE growth globally is going really well, and I'm looking forward to delivering on even stronger growth as we move into the next few years.
Yeah. That is great. And congrats on the Japan expansion here, and got to see the European launchâ
Yeah.
âstarting to kick in as well.
Yeah.
That is really great. Maybe when we talk about the DAYBUE STIX, I guess, and how that compares to the liquid. I mean, so far, the persistence that you have talked about has been pretty similarâ
Yeah.
âI believe. Is the idea here is that basically because of this sort of convenience of that you can mix it with any liquid, you are trying to really just expand the TAM for the patient and patient that might have either previously dropped out or naive patient that might not have considered or otherwise expand on that, but does not necessarily change the sort of the compliance and persistence of products?
Yeah, let me take those two things separately. The persistency is looking pretty similar. As you will appreciate, we only launched it in February, March, so there's still a relatively short timeframe for patients on STIX. But the persistency is tracking very similar to oil. What we do see is because these, we've seen quite a lot more restarts on DAYBUE STIX, is that some of those patients do not tolerate the trofinetide again, because it's the same active in both formulations. But what we are seeing is a benefit potentially in dose, so the percentage that the patient actually consumes versus the weight-banded stick. We are seeing some tick-ups in the patients that are on DAYBUE STIX because of that convenience. So the girls are able to tolerate a bit more in terms of the dosing.
So we're potentially seeing an upside to compliance to dose, but similar persistency.
Yeah, I mean, in terms of you have made some strides on improving the persistency as well, just around educating the caregivers and physician community, just if we can talk about some of these things andâ
Yeah.
âDo you think that has primarily played out at this point, or is there more additional progress?
No, I think it's probably played out. We're seeing a pretty steady state now in all of our cohorts. We map our cohorts over time, and we look for differences. We're at over 55% now at 12 months persistency, and we're seeing that kind of plateau out to two years, which is around about 50% at two years. We're seeing that very steady. That's due to the education, and also I think the physicians feel more confident in ensuring that patients are complying to the recommendations, which is stopping their anti-constipation medications, increasing their fiber. A lot of physicians feel more comfortable titrating the dose, so we're seeing a lot more of that now in terms of the dose titration. All of those things together are improving the persistency over time and making sure that we do not see those rates change too much.
Got it. Okay. When we think about the sort of the physician audience that you're going after, so right now only 30% penetrated in the community settingâ
Yeah.
âwhereas 80% of the referrals in Q3 came from community. How do you sort of expand the pieâ
Yeah.
âthat you're sort of getting more depth and breadth of prescribing?
Yeah. If we go back to the strategy for expanding the field force, it was to actually get into the community, and we're now seeing it play out, right? The increase we're now seeing in terms of patients starting in the community is really starting to play through. We're still only 30% penetrated in the community, as I said earlier, and so we expect that to increase over time. But we, I think 79% of our referrals in Q3 were from the community, so it's really starting to have an effect. And they grow in confidence, they're educated, we expect that to continue. Patients in the community maybe see one or two patients a year, and so they just have taken a little bit longer to educate and feel confident to prescribe DAYBUE.
But now that we're seeing that play through, I think there's more potential now to drive that penetration in the community setting.
Yeah. Can you remind us just the sort of the three segments of where the patients sit and what percentages are?
Yeah. I mean, there's really two segments ultimately. It's the Center of Excellence where about 30% of the patients sit, and then the community setting. Within there's a sort of a high-volume community setting, which you can sort of talk to. But essentially, there's 65% of patients in the community and 35% treated in the Center of Excellence.
Is the adoption of STIX or the persistence, compliance, any different between these two segments?
No, actually. We've looked at that, and they seem to be pretty similar in terms of the adoption, the compliance, and all the sort of the overview that we see of the patient. They seem to be pretty similar between the COEs and theâ
Okay. Great. Yeah. Any expectation that you would set sort of the contribution from the ex-U.S. revenue opportunity that you're working through?
Right now, we're going to continue to set guidance based on global sales. As and when the sales outside the U.S. reach a point where we think it's going to be useful to separate those two, we'll do it. But for right now, I think we've been fairly consistent in saying our expectation is around about sort of 10% of global sales will be outside the U.S. As that changes over time, we get more countries reimbursed, we'll give that guidance as we find it useful.
Yeah. That's great. Awesome. Let's talk about NUPLAZID. I mean, you've expanded the physician reach quite significantly, so now more than 5,000 physicians. The team is calling on for the first time and sort of also building out more relationship with physician that you had not targeted before.
Yeah.
What's the growth path based on all these efforts that you're starting to see for NUPLAZID?
Yeah. So we expanded our field force in Q1, Q2 this year. We've gone from a reach of about 5,000 physicians to 10,000, so the delta is the 5,000 new physicians. Those physicians are predominantly PCPs in the community, some neurologists, some psychiatrists, but mainly PCPs. The team are now up and running and fully automated, as it were, in the field.
Yeah.
We're seeing them now reach those additional customers. Obviously, when you're seeing a new customer for the first time, it takes a little bit longer to get in the door, get the appointment. Also what we're finding is it's taking a little longer with those conversations to actually get that first prescription of NUPLAZID. It is taking a little longer than we had initially anticipated. But now that we understand that curve, we believe the impact of the field force in terms of driving through the full funnel will be seen towards the end of this year and into next year. So we're seeing new prescriptions increase, we're seeing the referrals increase. So all the top- of- the- funnel dynamics we expected is happening. We now need to see that pull through in terms of the funnel.
Yeah. That's great. I mean, obviously one of the big debates on this is just around the IP, and this is one of the big positives that's played out that you have expanded that from 2030- 2038.
Yeah.
Now going through the appeals process right now.
Yeah.
There was an oral argument. Whatever you can comment around, just give the confidence of you think that the circuit court is going to affirm or whatever review the district court decision.
Yeah. I think we can comment that we believe the district court decision was well-supported by the facts and the applicable law, and we believe that the way that the panel will assess that will be against two standards. One is, was the correct legal standard applied by the district court? Second, were there any fundamental errors made in that application? We believe against those two areas, we stand by the decision that was made in the district court. As you know, the appeal panel is three judges, and it's difficult to assess how they're going to vote. We heard one judge was fairly vocal during that oral discussion. In terms of the process, it's a majority decision, so two out of the three judges have to align. We stand by the district court's decision. The panel will make their decision.
We do not exactly know when that decision's going to be. We believe it could be any time in the next few weeks, and it could be up to the middle of next year. It's difficult, as you know, with legal decisions, to put a timeframe on it. But we stand by the district court's decision, and we're eager to understand how the panel appeal goes through. But I think it's important to put all of that into context. The NUPLAZID lifecycle is such that we have the majority of our volume, sorry, the majority of our sales before the 2030 type timeframe, because during 2029, we're going to be under IRA negotiation for price. We'll see our price decrease through that IRA negotiation, which is the applicable situation right now.
Yeah.
We were assuming a decrease in net sales beyond 2030 anyway. We're covered by the small biotech exemption, so those decreases are capped for the first few years. But the majority of our growth sales are going to come before 2030 anyway.
Got it. Okay. That's why the focus on pipeline.
Exactly right.
Let's talk about the remlifanserin, ADP. I mean, you've shared the data. There is more coming today, I believe.
There is a CTAD presentation in a couple of hours in Boston, and we will be sharing a little bit more data during that. I cannot reveal that now, Ash.
Yeah.
Happy to share the deck, and I think our website will be updated with that deck within a few hours of that presentation, so investors will be able to look at the additional data.
Got it. Okay. That is great. Maybe I will just ask based on the top line that you have released. I think one of the things that has been a big topic of conversation here is the baseline disease activity, right? More enriching of patients has resulted in higher efficacy. I guess the way that you would think about it, is there more room for enrichment of this patient population beyond what yo u have done already? Is thatâ
Yeah.
âgive you still a reasonable time of patients to go after?
So, let me sort of thread that question through into how we're evolving the phase III study, because I think that's an important context to put it within. So it was a seamless enrollment trial, so the phase III study was already ongoing. The decision we've made in seeing the initial data is that there's definitely a dose effect between the 30 mg and the 60 mg. In this population, we've decided to drop the 30 mg arm and just continue with the 60 mg. So that's an operational design that we continue with. We're also going to evolve some of the sites, and as you expect in any clinical trial, some sites did better than others. So we're going to make some adjustments to site choice through the program.
We're also going to make an adjustment operationally to the way we train the sites and ensure that training is focused on removing as much subjectivity as we can from the scales, as well as increasing some other aspects of training. So in terms of the enrichment part of that evolution of the trial. We're looking to enrich through the statistical analysis plan and not through the inclusion and the exclusion criteria. We've already mentioned that we're looking to enrich based on severity, and there are some other patient characteristics that we're also looking at to additionally drive that enrichment. But we're not going to share exactly what that is because we want to ensure that we're not inducing bias in the trial by sharing that.
Because, as you know, the more physicians and patients know about enrichments and the patient types that we're looking for, the more potential there is for bias to be introduced into a trial, and we're trying to minimize that.
Got it. The study is still enrolling. You just started it, right?
Yes.
Would that data come before or after the Lewy body phase II?
The phase III trial for the ADP population will be after the phase II readout next year.
Yeah.
The endpoints of both phase III trials we haven't shared yet in terms of the expected timing. But the Lewy body phase II study is going to come out in Q4 of next year.
Got it. Okay. Yeah. Just coming back to this, in terms, I know you cannot share a lot of details, but I guess, when you think about these factors that you're sort of playing for, is it more just clinical, demographic, biomarker-related, or anything related to trial conduct?
I think we can say that the main enrichment strategy is going to be around patient characteristics.
Okay.
As you know, the biomarker strategy is already inherent within the trial. We're looking at patients that are biomarker-positive . That in itself has really affected the screening rate because we see quite a lot of dropouts during that screening for the biomarker as well as other areas. So, the enrichment will be around patient characteristics in the main, and severity will be one part of that. Beyond that, we're not going to be sharing the other patient characteristics that we're looking for enrichment.
Yeah. In terms of the clinical trial conduct, I know you've talked about that you want to use central raters, you find the site selection. I mean, what type of difference does that make, if you're using a central rater versus based on the site? Does that drive more consistency and takes out some, at least one variable out of the equation?
I think the way Sanjeev would answer that, who's our head of clinical development, is that previously in pimavanserin PDP trial, at the same point in time, we moved to more central raters in the phase III, and we just saw more consistency and objectivity and sort of similar standards in terms of using those central raters. We believe that helped us deliver the effect size that we achieved for that registrational trial. The use of central raters in psych trials is, as you know, fairly common, but we are really trying to drive hard behind that. We think it also is going to help sites who have smaller numbers of patients, maybe more limited qualified trial raters who might not always be available when the patient's there.
It achieves a number of things, but overall, we believe it achieves a more objective measure of the patient selection, and so we're trying to drive as much as we can towards central rating.
Yeah. I believe you have to have an end of phase II meeting with the FDAâ
Yeah.
âfor this, right? The phase III has started already?
Yeah.
So, yeah, what type of discussion pointsâ
Yeah.
âdo you bring on the table to talk through these?
Yeah. So it's end of phase II meeting will happen in the first half of next year. That will be really just to talk through some of the statistical analysis enrichment plan. It will also be to share a little bit more on the safety database and some non-CMC issues that we'll be sharing with the FDA. The seamless operational design of the study allows us, as an example, to drop the 30 mg arm without consulting with the FDA. So the discussion will be around that statistical analysis plan in the main. There'll also be another meeting with the FDA, a COA meeting in the first half of next year, where we will be discussing more around the endpoints and getting alignment with the FDA on the choice of primary endpoint.
Got it. Could that change this, the SAPS-H+D versus I know there's been a fair amount ofâ
I mean, it could evolve. We believe the SAPS-H+D is the right endpoint for remlifanserin, and we will go into the FDA with that package. But again, endpoint discussions can evolve, and as and when they do, we will share that. But we are feeling very confident in SAPS-H+D in terms of our primary endpoint.
Great. Okay. So maybe just spending a few minutes on the Lewy body. If you can talk about that. I know you mentioned this, that the ADP findings kind of increased your confidence in Lewy body, just based off the historical pimavanserin experience, right? If you can talk about what is kind of driving that.
Yeah. So in terms of the pimavanserin trials that we have done that included Lewy body patients, there are three studies that we have completed. The first is the 020 pivotal study for pimavanserin in PDP, and within that study, there were 50 patients who were Lewy body dementia psychosis patients. And we saw in that subgroup twice the effect size than we did in the overall population. The second trial was the HARMONY trial, which was the randomized withdrawal trial, and this is the data we shared on the slide at the R&D Day, and there were 44 patients in that trial that were randomized for pimavanserin or placebo in the Lewy body patient population. And in that randomized withdrawal, we saw a 5% relapse rate for pimavanserin and a 52% relapse rate for placebo. So again, there was a marked effect size there.
And the final study is a study that we have not actually published. It is data on file. It is called the 046 study, and it is in a subpopulation of Lewy body patients in a neurodegenerative trial that we did with pimavanserin. There were 42 patients in that study. And this is against an endpoint of CGI, and we saw a 0.7 effect size in that subgroup of Lewy body patients. So, you can see smaller subgroups of patients, but consistently we are seeing higher effect sizes in the Lewy body population. Now, again, the phase II will answer the question, so we are not predicting that outcome, but in terms of the confidence going in, that is what that is based on.
Got it. Yeah. I guess for ADP, you have had a fair bit of data that you have collected, so you sort of understand what is a more sensitive endpoint, what dose works, and what type of sort of enrichment that you need to do. I think on Lewy body, these questions need to be still answered.
Yeah.
Okay. I am just thinking about it from that standpoint that, yeah, you have generated data, and is the thought process that you feel confident in Lewy body because of the prior data that exists? But some of theâ
I think it is both, Ash.
Yeah.
I think it is a good link into the other confidence that we have seen in the ADP trial is the very favorable safety profile. As we move into Lewy body dementia psychosis, those patients are more frail generally than an Alzheimer's population. They tend to be more sensitive to off-label antipsychotics. They tend to be more sensitive generally to side effects. Having seen the side effect profile in the ADP population, where we saw side effects similar to placebo, we are hoping that, again, that plays out in the LBDP population in terms of a potential efficacy profile that we have seen with pimavanserin and safety profile we have now seen with remlifanserin. Those two things come together to offer a potentially quite a compelling package for that patient population. But again, we will see what happens in the phase II study.
The other part of that is that we are continuing with the 30 mg arm in the LBDP study. We are not going to drop that because of wanting to see both arms in terms of efficacy and also safety. We believe it is important to see that safety profile at both doses in this specific population.
Is that the one-on-one randomization?
It is. One-on-one, yeah.
Okay. Got it. This data is second half next year?
Q4.
Q4. Okay, great. All right. I know you just talked about recently ACP-211.
Yeah.
Yeah, I mean, a lot of excitement around just psychedelic and psychedelic-like programs, right? But just at-home infusion can add another dimension of convenience to these type of therapies, of course. If you can just kind of talk about, like, where do you think this can sit within the treatment paradigm?
Y eah. ACP-211 is deuterated R-norketamine.
Right.
It's a metabolite of ketamine that is the R-isomer that's been deuterated. It's an NMDA antagonist, so the antidepressant effect we believe, we hope is similar to SPRAVATO. This is an oral dose that is taken twice a week, and the aspiration is to have a patient experience and a safety profile that allows us to take this from the in-office or in-clinic dosing that we see with SPRAVATO potentially to the home. The opportunity for ACP-211 is to have SPRAVATO-like efficacy with a safety profile that allows it to be dosed at home, which is a much more convenient situation for both doctors and patients. As you know, right now, they have to be monitored in an office. Versus psychedelics, that's a different opportunity. Psychedelics are actively trying to induce an altered state of mind.
Yeah.
Right? They are actively trying to have a patient in an altered state of mind for a period of hours to try and induce that antidepressant effect. As you know, it is a sort of six- to eight-hour experience, highly controlled, highly monitored. Then potentially, the patient does not have to be dosed again for a while anyway. So it is a completely different approach to treating depression. We think there is room for both. I think the psychedelic commercial challenge is going to be real. I think it is new, that is for sure.
Yeah.
It will be a different approach. But I think with sort of 21 million patients in the U.S. having major depressive disorder, there is certainly room for innovation. We all know there is a huge unmet need. There is room for different approaches, and we think that ACP-211, should it come through in terms of the efficacy and safety profile I have just described, would definitely serve a population of patients where that would be a very attractive profile.
Yeah. Great. Awesome. With that, we are right on time.
Well done.
Thank you so much for this. And yeah, good luck with all these programs, and we will talk more.
Thank you, Ashâ
Yeah.
âappreciate the time.
All right. Thanks Catherine .